Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

66.95 +1.24 (+1.89%)
Streaming Delayed Price Updated: 3:38 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Ther

< Previous 1 2 3 4 5 Next >
Analyst Ratings For Intra-Cellular Therapies
Via Benzinga
ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024
ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
Via Benzinga
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Intra-Cellular Therapies?
Via Benzinga
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
Via Benzinga
Where Intra-Cellular Therapies Stands With Analysts
Via Benzinga
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
Via Benzinga
Expert Ratings for Intra-Cellular Therapies
Via Benzinga
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants. 
Via Benzinga
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Intra-Cellular Therapies's Earnings: A Preview
Via Benzinga
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are... 
Via Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.